According to the Complaint, bluebird bio, Inc. is a biotechnology company that engages in researching, developing, and commercializing transformative gene therapies for severe genetic diseases and cancer. The company’s gene therapy programs include, among others, LentiGlobin (bb1111) for the treatment of SCD. In May 2020, in the midst of the COVID-19 pandemic, bluebird announced that the Company expected to submit a BLA to the FDA for LentiGlobin for SCD in the second half of 2021.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (ii) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (iii) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

On February 26, 2021, this case was transferred to the District of Massachusetts.

The Court issued an Order appointing Lead Plaintiff and Counsel on May 4, 2021. On July 6, Lead Plaintiff filed an amended Complaint. Defendants filed a Motion to Dismiss the amended Complaint on September 7.

On April 21, 2022, the Court issued an Order granting Defendants' Motion to Dismiss. The case was dismissed with prejudice.